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Summary
An autosomal dominant presenile dementia affecting 39
individuals in a seven-generation, 383-member pedigree
has been studied at Indiana University. In the affected
members of this family, clinical symptoms occurred early
in life, with an average age at onset of 48.8 years. The
presenting clinical features include disequilibrium, neck
stiffness, dysphagia, and memory loss. As the disease
progresses, further cognitive decline, superior-gaze palsy,
and dystaxia also are observed. The average duration
from onset of symptoms to death is ∼10 years.
Neuropathologic studies of nine affected individuals
showed neuronal loss in several areas of the CNS, as
well as argentophilic tau-immunopositive inclusions in
neurons and in oligodendroglia. A limited genomic
screen by use of DNA samples from 28 family members
localized the gene for this disorder to a 3-cM region on
chromosome 17, between the markers THRA1 and
D17S791. The gene for tau also was analyzed, through
samples from the family.
Introduction
Recently, five studies (Wilhelmsen et al. 1994; Brown et
al. 1995; Wijker et al. 1996; Yamaoka et al. 1996; Heu-
tink et al. 1997) have described seven large pedigrees
with different autosomal dominant forms of presenile
frontotemporal dementia. In one family, affected indi-
viduals had personality changes, and some members
were diagnosed as having schizophrenia and parkinson-
ism (Wilhelmsen et al. 1994). This condition was named
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disinhibition-dementia-parkinsonism-amyotrophy com-
plex (DDPAC). A second family showed a nonspecific
dementia that has been linked to chromosome 3 (Brown
et al. 1995). Pallido-ponto-nigral degeneration (PPND)
with parkinsonism and dementia characterized the third
family (Wijker et al. 1996). The fourth family was de-
scribed as having a non–Alzheimer disease dementia (Ya-
maoka et al. 1996). Finally, three Dutch families with
hereditary frontotemporal dementia characterized by be-
havioral changes and speech problems were described
recently (Heutink et al. 1997). Six of these seven families
are linked genetically to chromosome 17q21-22.
Clinically and pathologically these disorders appear
to be distinct from one another. Although general find-
ings, such as the absence of b-amyloid and a variability
of neurofibrillary changes, have been described, exten-
sive pathological studies have not been performed for
most of these reported disorders.
We recently have described a seven-generation, 383-
member pedigree with an autosomal dominant neuro-
logical disorder (Ghetti and Farlow 1994). In affected
members of the family, the clinical symptoms appeared
at an average age of 48.8 years (range 39–59 years), and
the duration of the disease was 10 years. The initial
clinical features included disequilibrium, neck stiffness,
dysphagia, and memory loss. In later stages of the dis-
ease, further cognitive decline, dystaxia, and extrapyr-
amidal signs, including marked superior-gaze palsy, were
observed.
Neuropathological studies revealed neuronal loss in
several cortical areas. These regions showed argento-
philic tau-immunopositive inclusions. Twisted filaments
composed of tau protein also were observed. These dif-
fered, in diameter and periodicity, from the paired helical
filaments of Alzheimer disease (Spillantini et al. 1997).
Because of the clinical and pathological characteristics
of this family, the disease has been named “familial mul-
tiple-system tauopathy with presenile dementia”
(“MSTD”).
Determination of the genetic location of MSTD was
deemed important for identification of the gene causing
this disorder. Chromosome 17 was one logical location
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Figure 1 Pedigree of the MSTD family. Blackened symbols denote affected individuals. To obtain DNA samples, blood was drawn from
all individuals who were clinically examined (indicated by “E1”). “E2” indicates those individuals on whom an autopsy was performed. An
asterisk (*) indicates that an evaluation was documented.
to start a genetic screen, because of (1) the pathological
involvement of tau and the fact that the tau gene is
localized to 17q21-22 and (2) the fact that the other
disorders also had been linked to the same chromosomal
region as the tau gene. However, genetic screening of
those chromosomes known to harbor genes that cause
dementia also was undertaken for this family, in the hope
that one of these locations possibly might provide link-
age. The chromosomes associated with Alzheimer dis-
ease, familial nonspecific dementia (Brown et al. 1995),
prion diseases, and the frontotemporal dementias were
examined. This article presents the results of this genetic
study and an analysis of the tau gene as a candidate for
MSTD.
Material and Methods
Informed consent for these studies was obtained from
the participating family members. A pedigree is shown
in figure 1. Blood or tissue samples from 48 individuals
were collected. Eleven of these samples were from af-
fected individuals. Five of these 11 patients had been
examined by a neurologist, and autopsies with neuro-
pathologic evaluations had been performed on 9 of the
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patients. Three affected individuals were examined both
neurologically and pathologically. The diagnosis of
MSTD was based on these neurological exams and/or
neuropathological studies.
For the neuropathologic studies, tissue blocks and
slides were prepared by use of methods described else-
where (Ghetti et al. 1996). The 10-mm sections were
incubated with monoclonal antibodies raised against
tau, such as phosphorylation-dependent AT8, and
PHF1 (1:500) and phosphorylation-independent Alz50
(1:500). For detection of the b-amyloid protein, themon-
oclonal antibody 10D5 (1:500) was used (Knops et al.
1991). The peroxidase-antiperoxidase method, using
the peroxidase substrates 3,3′-diaminobenzidine and
0.015% H2O2, was used for immunodetection (Ghetti
et al. 1992).
DNA samples from 28 members of the family were
used for the genomic screen, because these samples pro-
vided the most information for the linkage analyses.
Genotypic studies focused on a few candidate regions
on chromosomes 1 and 3 and on the entire chromosome
for chromosomes 14, 17, 19, 20, and 21. Microsatellite
primer pairs were obtained from Research Genetics.
Markers were selected either to span the whole chro-
mosome of interest, with ∼10-cM spacing, or to sur-
round and include the disease-gene locus, within 10 cM,
in the case of chromosomes 1 and 3.
Genomic DNA from blood samples was isolated by
proteinase K digestion, phenol-chloroform extraction,
and precipitation in isopropanol. Six DNA samples were
obtained from histological sections, by use of the pro-
tocol described by Nichols et al. (1990). Markers were
analyzed by the end-labeling of one primer, with
[g-32P]ATP, and by use of this primer with a paired un-
labeled primer, to amplify 20 ng of genomic DNA. The
products were separated by use of 6%-polyacrylamide/
8 M–urea gel electrophoresis. Gels were dried and were
exposed to film. Allele sizes were determined by com-
parison with known alleles of CEPH parents 1331-01
and 1331-02; however, when the allele size was unclear,
the sequence of a molecular-weight standard was used
to determine exact size.
Examination of the pedigree clearly indicated auto-
somal dominant transmission of MSTD, in this family.
All affected individuals have an affected parent, implying
a highly, if not fully, penetrant disorder. In the family,
the earliest age at onset was 39 years, and the latest age
at onset was 59 years. Owing to the small number of
individuals with a well-established age at onset in this
family, a simple penetrance function was modeled, with
zero penetrance from birth to age 35 years then an in-
crease in a linear fashion until age 60 years, when the
maximum penetrance of 99% is reached. The frequency
of the disease gene was assumed to be 1/1,000 chro-
mosomes in the population, and the LOD scores cal-
culated were stable across order-of-magnitude changes
in this estimate, as well as across changes in the pene-
trance function. Allele frequencies and recombination
frequencies between loci used in the analyses were taken
from the on-line CEPH-Ge´ne´thon database (http://
www.cephb.fr/bio/ceph-genethon-map.html), the Ge-
nome Database (http://gdbwww.gdb.org/), and the Co-
operative Human Linkage Center database (http://
www.chlc.org/). The frequencies of the marker alleles
also were estimated for this family by use of the
USERM13 subroutine of the MENDEL suite of pro-
grams. The allele-frequency estimates from this program
were similar to those reported in the CEPH-
Ge´ne´thon database (http://www.cephb.fr/bio/ceph-
genethon-map.html). The MLINK program from the
FASTLINK, version 3.0, package (Schaffer et al. 1994)
was used to perform pairwise LOD-score analysis.
Multipoint analyses were performedwith the program
VITESSE (O’Connell and Weeks 1995). Owing to the
presence of multiple generations of nongenotyped per-
sons, at the top of the pedigree, the family was split into
two parts, so that the multipoint calculations would be
computationally feasible. Two-point LOD scores were
computed for the split pedigree, and, whereas the max-
imum LOD score for each marker was slightly decreased
as compared with the maximum score for the pedigree
analyzed in its entirety, all information regarding recom-
bination was preserved. The nine most informative
markers, spanning the region of chromosome 17 impli-
cated by the two-point results, were included in the mul-
tipoint analyses. For the disease locus, likelihoods were
calculated by use of three marker loci at a time, to keep
the computation time reasonable (∼1.5 d/calculation). A
window of three marker loci was moved along the map
of nine markers, one marker at a time, and multipoint
analysis was performed for overlapping groups, each
comprising three adjacent markers.
Sequencing of the tau gene was performed by direct
sequencing, as described in the study by Nichols et al.
(1990). Primers from the intronic sequences flanking
each exon were used so that the entire exon sequence
and the splice signals could be analyzed. Sequences were
compared to that of a normal control and to the pub-
lished tau-gene sequence.
Results
Linkage analysis was performed for this family. Be-
cause of the similarity of MSTD to other inherited de-
mentias, chromosomes harboring genes associated with
those dementias were analyzed. Most of the candidate
regions, such as chromosomes 14, 19, 20, and 21, were
excluded by use of two-point LOD scores of X2.00
(data not shown). A 15-cM region (six markers) around
the presenilin II gene on chromosome 1 and a 50-cM
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Table 1




LOD SCORE AT RECOMBINATION FRACTION OF
Zmax vmax.00 .01 .05 .10 .20 .30 .40
D17S969 4.22 .83 .24 .08 .01 .01 .01 .00 50.0
D17S798
28.0
2.90 .76 1.31 1.37 1.12 .69 .26 1.38 8.8
D17S1293
3.0
2.32 1.09 1.51 1.48 1.12 .68 .24 1.53 6.4
D17S946
4.0
2.28 .54 1.07 1.15 .97 .64 .27 1.15 9.5
D17S250
3.0
1.63 1.59 1.42 1.22 .83 .47 .16 1.63 .0
THRA1
2.0
3.40 .08 .43 .50 .38 .21 .08 .50 9.6
D17S800
1.0
.41 .39 .34 .27 .15 .08 .03 .41 .0
D17S932
1.0
2.06 2.04 1.91 1.73 1.29 .79 .28 2.06 .0
D17S934
1.0
.93 .88 .71 .50 .14 .04 .03 .93 .0
D17S951
.0
2.24 2.19 1.98 1.71 1.18 .69 .25 2.24 .0
D17S579
.0
1.78 1.74 1.63 1.51 1.21 .82 .35 1.78 .0
D17S930
1.0
.95 .94 .86 .75 .51 .28 .10 .95 .0
D17S810
.0
3.30 3.23 2.97 2.64 1.93 1.21 .50 3.30 .0
D17S791
.0
1.14 4.75 5.00 4.72 3.78 2.61 1.30 5.02 3.9
D17S806
3.0
.50 3.11 3.44 3.27 2.58 1.74 .84 3.44 4.6
HOX2B
.0
2.18 2.13 1.92 1.66 1.15 .65 .18 2.18 .0
D17S943
3.0
1.78 1.74 1.58 1.37 .95 .53 .18 1.78 .0
D17S788
4.0
.07 .07 .08 .09 .10 .08 .05 .00 50.0
D17S787
3.0
1.90 1.87 1.73 1.55 1.14 .69 .26 1.90 .0
D17S1290
5.0
7.22 .70 .51 .86 .89 .59 .18 .94 14.9
D17S968
20.0
5.06 1.92 1.05 .65 .29 .12 .03 .00 50.0
a Indicates the distance between the markers.
Figure 2 Recombinations defining the critical region forMSTD.
Each individual is from generation IV, and the individual number refers
to the pedigree shown in figure 1. Individuals IV-43 and IV-44 (brother
and sister) are second cousins of individuals IV-33 and IV-36 (sisters).
Individual IV-43, who is recombinant for markers D17S791 and
D17S806, is a deceased affected member of the family. Diagnosis was
established by neuropathological studies. Proximal recombination at
markers THRA1 and D17S946 was seen in two sisters, individuals
IV-33 and IV-36. Individual IV-33 is still living and was diagnosed
clinically, and individual IV-36 is deceased and was diagnosed with
MSTD by use of neuropathologic studies. An additional recombination
with marker D17S946 was seen in individual IV-44, the deceased af-
fected sister of individual IV-43. Individual IV-44 was diagnosed clin-
ically and was confirmed at autopsy to have had MSTD.
region (seven markers) flanking the familial nonspecific
dementia locus on chromosome 3 also were excluded as
the disease locus (data not shown). Linkage to chro-
mosome 17 was determined when two markers on the
q arm showed LOD scores 13.0. The highest two-point
LOD score was 5.00 with D17S791, at a distance of
. Table 1 summarizes the two-point linkage re-v  0.05
sults between the 17q markers and the disease locus.
The distance between the markers is given in centimor-
gans, in the second column. On the basis of recombi-
nation in this family, the MSTD locus was found to be
flanked by the markers THRA1 and D17S791 (fig. 2).
Seven markers between THRA1 andD17S791 have been
analyzed. None of the seven markers have recombina-
tion with the disease gene, and all affected individuals
share the same marker haplotype, in this chromosomal
region (fig. 2).
Multipoint analysis using three adjacent pairs of
marker loci resulted in a maximum multilocus LOD
score of 5.10, between the markers D17S932 and
D17S810 (fig. 3). Not all the markers were informative;
thus, the candidate region still could be reduced by ex-
amination of additional markers in this region, once they
become available.
Since linkage to chromosome 17 in the region of tau
was found, the open reading frame of tau was sequenced
in key members of the family. Polymorphisms were
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Figure 3 Results of multipoint linkage analyses between the
MSTD locus and nine markers on chromosome 17q21-22. Themarker
names are indicated below the X-axis.
found within exons 7, 8, and 9. These variations in se-
quence also were present in a normal control.
The neuropathologic studies of a recently deceased
affected member of the family showed neuronal loss in
several cortical areas, the basal ganglia, the hypothala-
mus, the substantia nigra, and several nuclei of the brain
stem. These regions also showed neuronal argentophilic,
tau-immunopositive inclusions (fig. 4). Similar intracel-
lular inclusions also were seen in oligodendroglial cells
in both the gray and the white matter. The tau deposits
were immunolabeled with both phosphorylation-de-
pendent and phosphorylation-independent antitau
antibodies.
Discussion
This study reports the mapping of the gene for MSTD
to a 3-cM region on chromosome 17q21-22. Analysis
of recombination events localized the gene between the
markers THRA1 and D17S791. All affected family
members have the so-called affected haplotype for mark-
ers within this region.
MSTD has a severe tauopathy in neurons and in oli-
godendroglia. It is interesting that the tau gene also is
located in the same chromosomal region as the gene for
MSTD, making it an excellent candidate gene for
MSTD. The tau gene has been mapped to 17q21 by
three different methods: in situ hybridization (Neve
et al. 1986), radiation hybrid mapping (Abel et al.
1993), and physical mapping using YACs (CEPH-
Ge´ne´thon database [http://www.cephb.fr/bio/ceph-
genethon-map.html]). The YACs localize tau between
the markers D17S951 and D17S930.
Tau functions as a cytoskeletal protein involved in the
polymerization of microtubules from soluble cytosolic
tubulin. The gene for tau extends over 100 kb. Within
the noncoding region of tau is a polymorphic dinucleo-
tide repeat that has been described recently (Conrad et
al. 1997). This polymorphism was analyzed through
study of the MSTD family. All the affected individuals
shared one allele (A3), which was to be expected, since
all affected individuals have the same haplotype in the
critical region. However, the marker was not very in-
formative, with only two alleles (A0 and A3) segregating
in the entire family and with nonaffected married-in in-
dividuals also carrying the A3 allele.
The tau gene has 15 exons, which are 54–753 bp in
size. Intron-exon junctions have been sequenced, which
would allow for sequence analysis of patient genomic
DNA (Andreadis et al. 1992). All exons have been se-
quenced in key members of the family, and polymor-
phisms have been found in exons 7, 8, and 9. The pro-
moter region and some intronic regions of tau are being
examined currently.
Several other familial dementias have been localized
to chromosome 17q21-22. These include PPND (Wszo-
lek et al. 1992; Yamada et al. 1993; Wijker et al. 1996),
DDPAC (Lynch et al. 1994;Wilhelmsen et al. 1994; Sima
et al. 1996), familial progressive subcortical gliosis (PSG)
(Lanska et al. 1994; Petersen et al. 1995), and frontal
lobe dementia (FLD) (Groen and Endtz 1982) and fron-
totemporal dementia (FLDEM) (Yamaoka et al. 1996;
Heutink et al. 1997). All of these diseases, including
MSTD, are autosomal dominant neurodegenerative dis-
eases with presenile dementia. They differ, however, in
clinical and pathological presentations. FLD, DDPAC,
PSG, and FLDEM individuals show behavioral and per-
sonality changes, with frontotemporal lobe atrophy
(Groen and Endtz 1982; Wilhelmsen et al. 1994; Peter-
sen et al. 1995; Yamaoka et al. 1996). Parkinsonism is
seen with PPND, DDPAC, MSTD, and FLDEM (Wszo-
lek et al. 1992; Ghetti and Farlow 1994; Lynch et al.
1994; Yamaoka et al. 1996). Abnormalities in ocular
motility are exhibited with PPND, MSTD, and PSG
(Wszolek et al. 1992; Ghetti and Farlow 1994; Petersen
et al. 1995). Neuronal loss is severe in all these diseases,
except in PSG in which the hallmark pathological feature
is astrocytic proliferation in subcortical white matter
(Lanska et al. 1994). None of these diseases show am-
yloid deposits or Lewy bodies. PPND, MSTD, and
DDPAC brains show the presence of tau pathology (Ya-
mada et al. 1993; Ghetti and Farlow 1994; Sima et al.
1996).
In spite of these phenotypic differences, it is possible
that this group of diseases could be allelic, as evidenced
by the mapping data. Although some of the diseases
linked to this region do not show tau pathology, this
fact does not necessarily eliminate this gene. However,
our current gene analyses do not support tau as the
disease gene. The single gene could be a gene other than
tau. It is known that mutations within a specific gene
can result in different clinical and pathological pheno-
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Figure 4 A, Cingulate cortex from an MSTD brain, showing tau-immunopositive neurons, neuropil threads, and occasional oligoden-
groglial cells. Immunoreactivity was seen by use of the monoclonal antibody AT8. B, Cingulate cortex from a normal brain, showing lack of
tau immunopositivity, by use of the monoclonal antibody AT8. C, White matter from an MSTD brain, showing numerous tau-immunopositive
oligodendroglial cells. Immunoreactivity was seen by use of the monoclonal antibody AT8. D, White matter from control brain, showing lack
of tau immunopositivity, by use of monoclonal antibody AT8. Magnification in each panel is #192.
typic expression in different families, as in the case of
prion-associated diseases (Goldfarb et al. 1994; Ghetti
et al. 1995).
Another possibility could be that there are two genes
or a family of genes in this region that are responsible
for these disorders. Another gene, that for glial fibrillary
acidic protein, also maps to 17q21 (Bongcam-Rudloff
et al. 1991) and could be a good candidate for those
diseases with or without tau pathology. Tau is involved
in many other neurodegenerative diseases but, so far,
has not been implicated as the principle cause of any of
them. Thus, it would be prudent to analyze additional
candidate genes that map to the region. Several public
databases list genes that map within this region.
The UniGene database (http://www.ncbi.nlm.nih.gov/
UniGene) (Schuler et al. 1996) lists 86 expressed-se-
quence tags or genes that map within D17S800 and
D17S791. Of these 86, 41 are known to be expressed
in the brain. The use of such databases would be a good
start to the finding of additional candidate genes for
MSTD.
Determination of the gene responsible for MSTD
would contribute to the understanding of the etiopath-
ogenic pathways of neuronal degeneration and eventu-
ally to the prevention of the process. Therefore, future
research with the MSTD pedigree will include the anal-
ysis of other candidate genes and the testing of additional
informative markers when available, in order to resolve
further the location of MSTD, so that positional cloning
can be pursued.
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